CO90 Matching-Adjusted Indirect Comparison of Efficacy and Safety for Lebrikizumab, Dupilumab, and Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled or Non-eligible for Cyclosporine
Abstract
Authors
K Ezzedine G Caillet JM Joubert K Rand A. Estévez-Carrillo B Akmaz L. Solé-Feu